VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
1.580
-0.120 (-7.06%)
Mar 31, 2025, 4:00 PM EDT - Market closed
VYNE Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 0.5 | 0.42 | 0.48 | 0.93 | 20.99 | Upgrade
|
| Revenue | 0.5 | 0.42 | 0.48 | 0.93 | 20.99 | Upgrade
|
| Revenue Growth (YoY) | 18.16% | -11.11% | -48.77% | -95.56% | 4638.83% | Upgrade
|
| Cost of Revenue | - | - | - | - | 1.39 | Upgrade
|
| Gross Profit | 0.5 | 0.42 | 0.48 | 0.93 | 19.6 | Upgrade
|
| Selling, General & Admin | 13.19 | 13.38 | 16.39 | 20.3 | 89.54 | Upgrade
|
| Research & Development | 30.95 | 16.31 | 18.39 | 19.54 | 43.53 | Upgrade
|
| Operating Expenses | 44.14 | 29.68 | 34.77 | 39.84 | 133.08 | Upgrade
|
| Operating Income | -43.64 | -29.26 | -34.3 | -38.91 | -113.48 | Upgrade
|
| Interest Expense | - | - | - | -5.61 | -4.39 | Upgrade
|
| Interest & Investment Income | 3.83 | 1.39 | 0.36 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -0.14 | 0.97 | Upgrade
|
| EBT Excluding Unusual Items | -39.8 | -27.87 | -33.93 | -44.66 | -116.9 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -4.55 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.14 | Upgrade
|
| Other Unusual Items | - | - | - | - | -84.73 | Upgrade
|
| Pretax Income | -39.8 | -27.87 | -33.93 | -44.66 | -255.83 | Upgrade
|
| Income Tax Expense | 0 | - | 0.01 | -0.45 | -0.26 | Upgrade
|
| Earnings From Continuing Operations | -39.81 | -27.87 | -33.95 | -44.21 | -255.57 | Upgrade
|
| Earnings From Discontinued Operations | -0.03 | -0.58 | 10.74 | -29.12 | - | Upgrade
|
| Net Income | -39.83 | -28.45 | -23.21 | -73.33 | -255.57 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 0.15 | - | - | - | Upgrade
|
| Net Income to Common | -39.83 | -28.6 | -23.21 | -73.33 | -255.57 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 10 | 3 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 43 | 10 | 3 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 314.57% | 222.44% | 11.44% | 58.75% | 282.06% | Upgrade
|
| EPS (Basic) | -0.94 | -2.78 | -7.28 | -25.65 | -141.90 | Upgrade
|
| EPS (Diluted) | -0.94 | -2.78 | -7.28 | -25.65 | -141.90 | Upgrade
|
| Free Cash Flow | -34.09 | -25.34 | -29.2 | -56.37 | -137.2 | Upgrade
|
| Free Cash Flow Per Share | -0.80 | -2.47 | -9.16 | -19.72 | -76.18 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 93.37% | Upgrade
|
| Operating Margin | -8709.98% | -6900.47% | -7189.73% | -4179.48% | -540.54% | Upgrade
|
| Profit Margin | -7950.90% | -6745.52% | -4865.83% | -7876.37% | -1217.40% | Upgrade
|
| Free Cash Flow Margin | -6804.19% | -5976.65% | -6121.59% | -6054.46% | -653.53% | Upgrade
|
| EBITDA | -43.63 | -29.19 | -34.22 | -38.8 | -113.13 | Upgrade
|
| D&A For EBITDA | 0 | 0.07 | 0.07 | 0.11 | 0.34 | Upgrade
|
| EBIT | -43.64 | -29.26 | -34.3 | -38.91 | -113.48 | Upgrade
|
| Revenue as Reported | 0.5 | 0.42 | 0.48 | 0.93 | 20.99 | Upgrade
|
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.